CD47 and breast cancer: The data presented by Cook et al. show that CD47 is regulated by lipid metabolism and UPR signaling, suggesting a new paradigm that may elucidate novel pathways to treat acquired resistance to anti-estrogen therapy, and thus improve clinical responses of breast cancer patients.